Visible gets $30 million equity injection:
This article was originally published in Clinica
Visible Genetics, an HIV diagnostics company which earlier this month announced restated sales and increased losses for the first quarter (see Clinica No 866, p 12), has secured a $30 million equity investment from EM Warburg Pincus. Warburg will get preference shares and a board seat on the company, while Toronto-based Visible will use the money to commercialise HIV, hepatitis B and C and tuberculosis genotyping diagnostics.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.